Inactivation of Wnt/β-catenin/renin angiotensin axis by tumor necrosis factor-alpha inhibitor, infliximab, ameliorates CKD induced in rats

pubmed: wnt1 2021-05-20

Summary:

Infliximab (IFX), a chimeric monoclonal antibody against tumor necrosis factor-α (TNF-α), is widely used to treat autoimmune diseases and chronic diseases associated with inflammation. TNF-α was reported to inhibit klotho, reactivate β-catenin and cause tubular cell injury in vitro. Whether the inhibition of TNF-α can regulate Wnt/β-catenin pathway via klotho in CKD in vivo is not studied yet. We aimed to investigate the impact of IFX on Wnt/β-catenin pathway in doxorubicin (DOX)-induced...

Link:

https://pubmed.ncbi.nlm.nih.gov/33482150/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=16uwQpOeqFYN8R4TKOtwPy2utpqy9ex2oldalD2yF_fQHv2caq&fc=None&ff=20210520032009&v=2.14.4

From feeds:

Exome » pubmed: wnt1

Tags:

Authors:

Nahla N Younis, Hoda E Mohamed, Mohamed A Shaheen, Asmaa M Abdelghafour, Sally K Hammad

Date tagged:

05/20/2021, 04:00

Date published:

01/22/2021, 06:00